Biomax Joins Austrian Personalized Medicine Consortium

Apr 25, 2008

NEW YORK (GenomeWeb News) - Biomax Informatics said this week that it has been selected as a consortium partner in Austria’s OncoTyrol project Center for Personalized Cancer Medicine.

The four-year, €28 million ($43.7 million) OncoTyrol initiative focuses on “translating genomic, proteomic and metabolomic research into innovative, individualized, and cost-effective approaches for cancer diagnosis and treatment,” Biomax said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Microsoft, But the Brain, Too

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

Been Reclassified

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

This Week in Cell

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

Pursuit of a Cancer Vaccine

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.

Main menu